NovoCure Tumor Treating Fields Shows Improved Outcomes In Tough Pancreatic Cancer

The stock is gaining traction as the company reported a disease control rate of 74.4%, significantly higher than the historical control of 48%.
Open original source
The stock is gaining traction as the company reported a disease control rate of 74.4%, significantly higher than the historical control of 48%.
Open original source